{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:31Z","timestamp":1786650091460,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>EGFR gene mutations are the second most common oncogenic driver of tumorigenesis in non-small cell lung cancer (NSCLC). Exon 19 deletions and L858R point mutation are strong predictors of response to TKIs, whereas rare EGFR mutations are generally associated with suboptimal TKIs response. Notably, rare mutations G719X and S768I can co-exist as complex mutations within the same tumor. In this context, we report a case of a 55-year-old female patient with left lower lobe lung adenocarcinoma along with metastases in the liver, skull, and bony pelvis. Histopathological examination of the right iliac bone confirmed the moderately differentiated metastatic adenocarcinoma. Findings of this report present the rare EGFR double mutations (G719X + S768I), along with concurrent ROS1positivity, which can directly affect treatment choices. There is ongoing debate about the optimal choice of TKI for the rare EGFR mutations, but earlier reports indicate that these mutations may respond more favorably to second-generation TKIs compared to first-generation. This report underscores the significance of thorough molecular profiling in NSCLC.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1835_25","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T17:01:01Z","timestamp":1767200461000},"page":"1446-1449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A rare case of lung adenocarcinoma with uncommon epidermal growth factor receptor gene double mutations: S768I + G719X"],"prefix":"10.4103","volume":"21","author":[{"given":"Deepti","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Pathology and Cancer Genetics, Kalyan Singh Super Specialty Cancer Institute, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cancer Genetics, Kalyan Singh Super Specialty Cancer Institute, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Kalyan Singh Super Specialty Cancer Institute, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somdatt","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cancer Genetics, Kalyan Singh Super Specialty Cancer Institute, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260102","first-page":"229","article-title":"Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260102","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"R3-20260102","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/ijerph20010758","article-title":"Mutational analysis of EGFR mutations in non-small cell lung carcinoma \u2013An Indian perspective of 212 patients","volume":"20","author":"Kaler","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R4-20260102","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/jcrt.jcrt_1898_23","article-title":"Histological transformation of non-small-cell lung cancer:A neglected entity","volume":"21","author":"Sanyal","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R5-20260102","doi-asserted-by":"crossref","first-page":"S712","DOI":"10.4103\/jcrt.jcrt_653_22","article-title":"Frequency of EGFR mutations in lung adenocarcinoma patients \u2013A study from tertiary cancer center of South India","volume":"19","author":"Nayanar","year":"2023","journal-title":"J Can Res Ther"},{"key":"R6-20260102","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14740\/wjon1204","article-title":"Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples:A molecular and immunohistochemical study","volume":"10","author":"Kumari","year":"2019","journal-title":"World J Oncol"},{"key":"R7-20260102","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1111\/1759-7714.15085","article-title":"A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma","volume":"14","author":"Morimoto","year":"2023","journal-title":"Thorac Cancer"},{"key":"R8-20260102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11523-016-0455-4","article-title":"Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I:A retrospective analysis and literature review","volume":"12","author":"Zhu","year":"2017","journal-title":"Target Oncol"},{"key":"R9-20260102","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2169\/internalmedicine.9565-17","article-title":"The effectiveness of afatinib in a patient with advanced lung adenocarcinoma harboring rare G719X and S768I mutations","volume":"57","author":"Watanabe","year":"2018","journal-title":"Intern Med"},{"key":"R10-20260102","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1835_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:58Z","timestamp":1786647718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1835_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1835_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}